2596

Raben, Adam; Sammons, Sara; Hanlon, A.; Sites, Karen; Schneider, C.; Koprowski, C.D.; Strasser, Jon

doi:10.1016/j.ijrobp.2006.07.1010

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The factors which result in cardiotoxicity as an adjuvant therapy can be classified based on the use of RT, use of chemotherapy regimens including anthracyclines or trastuzumab and the characteristics of the patient (6,(15)(16)(17). Cardiovascular complication related to RT is undeniable.…”

Section: Discussionmentioning

confidence: 99%

The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats

Cihan¹,

Arsav²

2014

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: This experimental study aims to investigate whether radiotherapy (RT) plus trastuzumab (T) followed by subsequent hormonotherapy increase the cumulative toxic effect on cardiac functions in rats. Methods: A total of 70 Wistar-Albino female rats with a mean weight 213±27 g were randomly divided into equal seven groups. The first group (C) underwent no procedure. The second group (RT) underwent the whole thoracic radiation including heart. The third group (T) was administered T through tail vein alone. The fourth group (RT+T+Tx) was administered T initially and the whole thoracic radiation at two hours, followed by tamoxifen at one week. The fifth group (RT+T+Le) was administered T and then underwent thoracic radiation, followed by letrozole. The sixth group (T+RT+An) was administered T and then underwent thoracic radiation, followed by anastrazole. The seventh group (T+RT+Ex) was administered T and then underwent thoracic radiation, followed by exemestane at one week. Hormonotherapy was administered to the rats in the Group 5, 6 and 7, as indicated in the Group 4. Radiation therapy was administered following T treatment at two hours as a single 12 Gy fraction. After the rats were sedated under anesthesia and sacrificed at 24 weeks, cardiac tissues were removed. Serial sections obtained following paraffin blockage were stained and the ratio of myocardial fibrosis was assessed. According to statistical analyses by the one-way ANOVA test and Tukey HSD test, a significant difference between test components. Results: At the end of the study, no loss and adverse effects were seen in any group. There was a statistically significant difference among atrium, ventricle and aorta (p<0.001). The mean value of fibrosis scores increased in the rats which underwent RT. In the assessment of atrium, a significant difference was found between RT group and RT+T+An group and also T group and RT+T+Fe group (p<0.001). In the assessment of ventricule, a statistically significant difference was observed among RT, RT+T+An and RT+T+Ex. In the assessment of aorta, the scores of RT group was significantly higher than RT+T+An and RT+T+Ex. A statistically significant difference was observed among these groups (p<0.001). Conclusion: Our study results suggested that there was no significant additional cardiotoxicity of adjuvant hormonotherapy following concomitant RT and T treatment, compared to RT in terms of cardiac fibrosis. (Anadolu Kardiyol Derg 2014; 14: 328-33)

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats

Cihan¹,

Arsav²

2014

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

show abstract

Concurrent Use of Radiation Therapy and Targeted Molecules in the Breast Cancer Treatment

Kirova

2017

Breast Cancer

View full text Add to dashboard Cite

Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study

Jacob

Belin

Pierga

et al. 2014

Breast Cancer Res Treat

View full text Add to dashboard Cite

This single-center prospective study aims to assess the outcomes and the toxicities related to the concurrent administration of trastuzumab (T) with adjuvant locoregional radiotherapy (RT) in localized breast cancer. Data of 308 patients were analyzed. T was delivered every 3 weeks (loading dose of 8 mg/kg, then 6 mg/kg) for 1 year. Left ventricular ejection fraction (LVEF), measured by echocardiography or myocardial scintigraphy, was considered as impaired when below 55%. Toxicities were assessed according to the Common Terminology Criteria for Adverse Events version 3.0. Univariate and multivariate analyses were carried out using the Cox model. Median follow-up was 50.2 months (13.0-126.0). Median age at diagnosis was 52 years (25-83). Internal mammary node (IMN) RT was performed in 227 patients (73.7%). After completion of RT, 26 patients (8.4%) presented an impaired LVEF: 17 (5.5%) of grade 1, 7 (2.3%) of grade 2, and 2 (0.6%) of grade 3. At 48 months, locoregional control rate was 95% [95% CI 92; 98], and overall survival rate was 98% [95% CI 96; 100]. In univariate analysis, neither the treated breast side (p = 0.655) nor IMN RT (p = 0.213) exposed patients to LVEF alteration. In multivariate analysis, clinical lymph node involvement was associated with an increased risk of locoregional and distant recurrence (p = 0.016 and p = 0.007, respectively). In this prospective study, the toxicities of concurrent T with locoregional breast RT were acceptable and the outcomes favorable. Longer follow-up is warranted to confirm these results.

show abstract

2596

Cited by 6 publications

References 0 publications

The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats

The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats

Concurrent Use of Radiation Therapy and Targeted Molecules in the Breast Cancer Treatment

Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study

Contact Info

Product

Resources

About